The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region

Nardone, A; Ory, Fernando de; Carton, Matthieu; Cohen, Dani; Damme, Pierre Van; Davidkin, Irja; Rota, Maria Cristina; Melker, Hester E. de; Mossong, Joël; Sláčiková, M; Tischer, Annedore; Andrews, Nick; Berbers, Guy A. M.; Gabutti, Giovanni; Jones, L.; Jokinen, Sari; Kafatos, George; Aragón, M.V. Martínez de; Schneider, François; Smetana, Zehava; Vargová, Blažena; Vranckx, R.; Miller, Elizabeth

doi:10.1016/j.vaccine.2007.07.036

Cited by 166 publications

(211 citation statements)

References 37 publications

Supporting

Mentioning

188

Contrasting

Unclassified

Order By: Relevance

“…In addition, there is a lack of a "gold standard" method for detecting anti-VZV IgG, which is why it is difficult to compare results between different studies. 31 Furthermore, and unlike other studies, 32 indeterminate results were not been included with positive results in this study, which is why the rates of seropositivity may be lower.…”

Section: Studymentioning

confidence: 98%

Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, andB. Pertussisin young adults of Madrid, Spain

González-Escalada

García-García

Viguera-Ester

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: Studymentioning

confidence: 98%

Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, andB. Pertussisin young adults of Madrid, Spain

González-Escalada

García-García

Viguera-Ester

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…Evidence partly supporting the EB hypothesis has cumulated [5][6][7], though its actual magnitude is yet to be determined adequately [8]. A large-scale European serology has indicated a lower HZ incidence by age in countries where varicella force of infection (FOI) is higher [2]. Nonetheless, contrary evidence also exists [9].…”

Section: Introductionmentioning

confidence: 99%

Perspectives on optimal control of varicella and herpes zoster by mass routine varicella vaccination

et al. 2016

View full text Add to dashboard Cite

Herpes zoster arises from reactivation of the varicella-zoster virus (VZV), causing varicella in children. As reactivation occurs when cell-mediated immunity (CMI) declines, and there is evidence that re-exposure to VZV boosts CMI, mass varicella immunization might increase the zoster burden, at least for some decades. Fear of this natural zoster boom is the main reason for the paralysis of varicella immunization in Europe. We apply optimal control to a realistically parametrized age-structured model for VZV transmission and reactivation to investigate whether feasible varicella immunization paths that are optimal in controlling both varicella and zoster exist. We analyse the optimality system numerically focusing on the role of the cost functional, of the relative zoster-varicella cost and of the planning horizon length. We show that optimal programmes will mostly be unfeasible for public health owing to their complex temporal profiles. This complexity is the consequence of the intrinsically antagonistic nature of varicella immunization programmes when aiming to control both varicella and zoster. However, we show that gradually increasing-hence feasible-vaccination schedules can perform better than routine programmes with constant vaccine uptake. Finally, we show the optimal profiles of feasible programmes targeting mitigation of the post-immunization natural zoster boom with priority.

show abstract

“…Therefore trends are either monitored regarding incidence in regional samples [1,8] or in sentinel surveys [10]. While trends in case ascertainment can be depicted by these approaches, quantifying vaccine effects and age-group interdependencies may require a more sophisticated approach.…”

Section: Introductionmentioning

confidence: 99%

Assessment of varicella vaccine effectiveness in Germany: a time-series approach

Höhle

Siedler

Bader³

et al. 2010

Epidemiol. Infect.

View full text Add to dashboard Cite

SUMMARYA multivariate time-series regression model was developed in order to describe the 2005-2008 age-specific time-course of varicella sentinel surveillance data following the introduction of a varicella childhood vaccination programme in Germany. This ecological approach allows the assessment of vaccine effectiveness under field conditions by relating vaccine coverage in cohorts of 24-month-old children to the mean number of cases per reporting unit in the sentinel network. For the 1-2 years age group, which is directly affected by the vaccination programme, a one-dose vaccine effectiveness of 83 . 2% (95 % CI 80 . 2-85 . 7) was estimated which corresponds to previous approaches assessing varicella vaccine effectiveness in the field in the USA.

show abstract

The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region

Cited by 166 publications

References 37 publications

Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, andB. Pertussisin young adults of Madrid, Spain

Seroprevalence of antibodies against measles, rubella, mumps, varicella-zoster, andB. Pertussisin young adults of Madrid, Spain

Perspectives on optimal control of varicella and herpes zoster by mass routine varicella vaccination

Assessment of varicella vaccine effectiveness in Germany: a time-series approach

Contact Info

Product

Resources

About